2023
Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Roseberry K, Le-Niculescu H, Levey D, Bhagar R, Soe K, Rogers J, Palkowitz S, Pina N, Anastasiadis W, Gill S, Kurian S, Shekhar A, Niculescu A. Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry 2023, 28: 2894-2912. PMID: 36878964, PMCID: PMC10615756, DOI: 10.1038/s41380-023-01998-0.Peer-Reviewed Original ResearchConceptsIndependent cohortCandidate biomarkersPsychiatric subjectsPersonalized approachConvergent functional genomics approachAnxiety disordersBest overall evidenceAdverse life eventsClinical worseningGene expression signaturesBlood biomarkersAnxiety medicationClinical utilityPsychiatric disordersHigh anxiety stateSevere anxietyUntreated anxietyDecrease qualityIndividual biomarkersAddiction potentialBiomarkersTop biomarkersAnxiety statesRisk predictionExpression signatures
2021
Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Le-Niculescu H, Roseberry K, Gill SS, Levey DF, Phalen PL, Mullen J, Williams A, Bhairo S, Voegtline T, Davis H, Shekhar A, Kurian SM, Niculescu AB. Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry 2021, 26: 2776-2804. PMID: 33828235, PMCID: PMC8505261, DOI: 10.1038/s41380-021-01061-w.Peer-Reviewed Original ResearchConceptsBlood gene expression biomarkersTop candidate biomarkersMood disordersIndependent cohortStrongest overall evidenceBlood testsTop biomarkersGene expression biomarkersCandidate biomarkersConvergent functional genomics approachMood statesPotential new antidepressantsPsychiatric disorder patientsOverall evidenceVisual analog scaleSimple visual analog scaleMatching of patientsPanel of biomarkersPrecision medicineMonitoring of responseBipolar mood disorderExpression biomarkersCell differentiation functionsObjective assessmentSevere maniaSex-stratified gene-by-environment genome-wide interaction study of trauma, posttraumatic-stress, and suicidality
Wendt FR, Pathak GA, Levey DF, Nuñez YZ, Overstreet C, Tyrrell C, Adhikari K, De Angelis F, Tylee DS, Goswami A, Krystal JH, Abdallah CG, Stein MB, Kranzler HR, Gelernter J, Polimanti R. Sex-stratified gene-by-environment genome-wide interaction study of trauma, posttraumatic-stress, and suicidality. Neurobiology Of Stress 2021, 14: 100309. PMID: 33665242, PMCID: PMC7905234, DOI: 10.1016/j.ynstr.2021.100309.Peer-Reviewed Original ResearchGenome-wide interaction studyRisk lociChromatin interaction profilesExtracellular matrix biologyGene-based analysisMatrix biologyMolecular basisTranscriptomic profilesInteraction studiesMultivariate geneGenetic perspectiveSNP effectsSuicidal behavior severityLociNovel targetGenesInteraction profilesSynaptic plasticityCellsInteractorsGenetic riskBiologyStressGxEIndependent cohort
2019
Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs
Niculescu A, Le-Niculescu H, Levey D, Roseberry K, Soe K, Rogers J, Khan F, Jones T, Judd S, McCormick M, Wessel A, Williams A, Kurian S, White F. Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs. Molecular Psychiatry 2019, 24: 501-522. PMID: 30755720, PMCID: PMC6477790, DOI: 10.1038/s41380-018-0345-5.Peer-Reviewed Original ResearchConceptsBlood gene expression biomarkersPossible new drug candidateFuture emergency department (ED) visitsEmergency department visitsHigh-risk groupDrug repurposing analysisCurrent opioid epidemicPerception of painSubjects longitudinal designGene expression signaturesPain statesDepartment visitsPain disordersTreatment dilemmaBlood biomarkersSC-560Opioid epidemicCohort designRisk groupsIndependent cohortPainGene expression biomarkersPsychiatric patientsDiagnostic biomarkersIndividual biomarkers
2017
Precision medicine for suicidality: from universality to subtypes and personalization
Niculescu A, Le-Niculescu H, Levey D, Phalen P, Dainton H, Roseberry K, Niculescu E, Niezer J, Williams A, Graham D, Jones T, Venugopal V, Ballew A, Yard M, Gelbart T, Kurian S, Shekhar A, Schork N, Sandusky G, Salomon D. Precision medicine for suicidality: from universality to subtypes and personalization. Molecular Psychiatry 2017, 22: 1250-1273. PMID: 28809398, PMCID: PMC5582166, DOI: 10.1038/mp.2017.128.Peer-Reviewed Original ResearchConceptsSuicidal ideationIndependent cohortPersonalized approachFuture hospitalizationPsychiatric diagnosisCandidate biomarkersUniversal biomarkerBlood gene expression biomarkersBiology of suicideTop biomarkersNovel predictive biomarkerHigh-risk groupNon-psychiatric disordersDrug repurposing analysisPublic health problemMonitoring of responseNovel potential therapeuticsHigher suicidal ideationPredictive biomarkersClinical trialsComprehensive stepwise approachRisk groupsLarge cohortMood disordersPreventive therapeutics